Calico Life Sciences LLC is an American biotechnology company with a focus on the biology of aging, attempting to devise interventions that may enable people to lead longer and healthier lives.

It is a subsidiary of Alphabet Inc. Calico, short for the California Life Company,[1][2] was announced on September 18, 2013, prior to Google's restructuring and was founded by former GV CEO Bill Maris.

[8] Some of the company’s earliest employees included the geneticist David Botstein, and cancer drug developer Robert L. Cohen, MD.,[9] Eric Verdin, CEO of The Buck Institute for Research on Aging, served as a consultant to the Calico team.

[10] At the end of 2017 and the beginning of 2018, Calico lost two top scientists; in December 2017 Hal Barron, MD, its head of R&D, left for GlaxoSmithKline, and in March 2018 chief computing officer Daphne Koller, who was leading their computational biology efforts, left to pursue a venture in applying machine learning techniques to drug design.

[20] In October 2023, Nature, a weekly British scientific journal, published preclinical research findings that showed ABBV-CLS-484, a PTPN2/N1 phosphatase inhibitor being co-developed by AbbVie and Calico, provokes a potent dual response in cancer and immune cells.